SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis (SAVE-AS)
Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Assess the Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitor in Patients With Aortic Valve Stenosis: SAVE-AS (SGLT2i Assessment Valvular Effect in AS)
Aortic stenosis (AS) is the most common valvular heart disease, and no medical therapy has been shown to slow its progression; treatment is limited to surgical or transcatheter aortic valve replacement once symptoms or left ventricular dysfunction develop. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death and heart failure hospitalization in patients with and without diabetes, and preclinical studies show that they suppress the inflammatory (NLRP3 inflammasome), fibrotic (TGF-beta/Smad), and oxidative-stress pathways that drive valve calcification. A recent observational study reported slower AS progression in patients treated with SGLT2 inhibitors.
SAVE-AS is a multicenter, prospective, randomized, double-blind, placebo-controlled, investigator-initiated superiority trial testing whether the SGLT2 inhibitor enavogliflozin (0.3 mg once daily) reduces the composite of all-cause death, aortic valve replacement, and hospitalization for heart failure in adults with asymptomatic moderate or severe aortic stenosis and preserved left ventricular ejection fraction (50% or higher). A total of 1,182 participants at 11 centers in the Republic of Korea will be randomized 1:1 to enavogliflozin or matching placebo, stratified by participating center and AS severity (moderate vs severe). Study treatment is given for 24 months, with follow-up visits at 2, 6, 12, 18, and 24 months and an end-of-treatment assessment at 25 months. Secondary outcomes include the individual components of the primary composite, cardiac death, echocardiographic AS severity, left ventricular mass, global longitudinal strain and ejection fraction, NT-proBNP, annual eGFR slope, and SGLT2 inhibitor-related adverse events. All clinical events are adjudicated by an independent clinical event adjudication committee, and safety is overseen by an independent data and safety monitoring board.
調査の概要
詳細な説明
Design: Prospective, multicenter (11 sites, Republic of Korea), randomized (1:1), double-blind, placebo-controlled, parallel-group, superiority, investigator-initiated trial. Randomization is performed centrally through an interactive web response system (IWRS) managed by an independent organization, stratified by participating center and baseline AS severity (moderate vs severe).
Population: Adults aged 19 years or older with asymptomatic (NYHA class I) moderate or severe aortic stenosis, defined as aortic valve area less than 1.5 cm2, peak aortic jet velocity 3 m/s or higher, or mean pressure gradient 25 mmHg or higher, with left ventricular ejection fraction 50% or higher. Patients meeting ACC/AHA or ESC/EACTS indications for aortic valve intervention, with very severe AS (peak velocity 5 m/s or higher or mean gradient 50 mmHg or higher), severe concomitant valve disease, eGFR below 30 mL/min/1.73 m2 or dialysis, type 1 diabetes, or SGLT2 inhibitor use within 3 months are excluded.
Intervention: Enavogliflozin 0.3 mg orally once daily or matching placebo for 24 months, on top of guideline-directed medical therapy per ACC/AHA/SCAI or ESC/EACTS recommendations. Concomitant medications may be adjusted at the investigator's discretion.
Schedule: Screening (day -90 to 0), baseline/randomization (day 0), visits at day 60 +/- 30, 180 +/- 30, 360 +/- 30, 540 +/- 30, and 720 +/- 30, and end-of-treatment assessment at day 750 +/- 90. Transthoracic echocardiography is performed at baseline, 12, and 24 months (and at 6 and 18 months in participants with severe AS at baseline). Laboratory tests (including eGFR), NT-proBNP and cardiac troponin T, ECG, and chest radiography are obtained at prespecified visits. Medication adherence is assessed at every visit. Clinical events are ascertained at each follow-up visit and at the end-of-treatment assessment at 25 months, and thereafter vital status and clinical events are ascertained by visit, telephone contact, or medical-record review until the end of study.
Sample size: Assuming an annual primary-event rate of 6% in the placebo group, a hazard ratio of 0.65, 3 years of accrual, 2 additional years of follow-up, 5% dropout, two-sided alpha of 0.05, and 80% power, 591 participants per group (1,182 total) are required (time-to-event analysis, log-rank test).
Analysis: Primary analysis by intention to treat; per-protocol analysis (adherence 70% or higher, no SGLT2 inhibitor use in the placebo group) as sensitivity analysis. Time-to-event outcomes are analyzed by Kaplan-Meier estimates, log-rank test, and Cox proportional-hazards models; continuous echocardiographic and laboratory outcomes by independent t-test. Participants lost to follow-up are censored. Prespecified subgroups: AS severity (moderate vs severe), age (below 70 vs 70 years or older), diabetes, hypertension, chronic kidney disease, and baseline global longitudinal strain. An interim analysis is planned when approximately 50% of the expected data have been collected, reviewed by the independent data and safety monitoring board.
Oversight: All primary and secondary clinical events are adjudicated by an independent Clinical Event Adjudication Committee. An independent Data and Safety Monitoring Board reviews all serious adverse events. Serious adverse events are reported to the principal investigator within 72 hours and to each site IRB per local requirements. The trial is conducted in accordance with the Declaration of Helsinki, ICH-GCP, and Korean GCP (KGCP).
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:GaHee Lee
- 電話番号:+82-2-2008-4135
- メール:gahee2.lee@sbri.co.kr
研究連絡先のバックアップ
- 名前:Jinseon Heo
- メール:jinseon.heo@sbri.co.kr
研究場所
-
-
-
Busan、韓国
- まだ募集していません
- Dong-A University Hospital
-
主任研究者:
- Kyung Hee Lim, MD, PhD
-
Changwon、韓国
- まだ募集していません
- Samsung Changwon Hospital
-
主任研究者:
- Mirae Lee, MD, PhD
-
Cheonan、韓国
- まだ募集していません
- Dankook University Hospital
-
主任研究者:
- Su Yeon Lee, MD, PhD
-
Gwangmyeong、韓国
- まだ募集していません
- Chung-Ang University Gwangmyeong Hospital
-
主任研究者:
- Eun Jeong Cho, MD, PhD
-
Seongnam、韓国
- まだ募集していません
- Seoul National University Bundang Hospital
-
主任研究者:
- Jiesuck Park, MD, PhD
-
Seoul、韓国、06351
- 募集
- Samsung Medical Center
-
コンタクト:
- GaHee Lee
- 電話番号:+82-2-2008-4135
- メール:gahee2.lee@sbri.co.kr
-
主任研究者:
- Sung-Ji Park, MD, PhD
-
Seoul、韓国
- まだ募集していません
- Korea University Anam Hospital
-
主任研究者:
- So Ree Kim, MD, PhD
-
Seoul、韓国
- まだ募集していません
- Kangbuk Samsung Hospital
-
主任研究者:
- Jiwon Kim, MD, PhD
-
Seoul、韓国
- まだ募集していません
- Konkuk University Medical Center
-
主任研究者:
- Sung Hea Kim, MD, PhD
-
Seoul、韓国
- まだ募集していません
- Asan Medical Center, University of Ulsan College of Medicine
-
主任研究者:
- Dae-Hee Kim, MD, PhD
-
Seoul、韓国
- まだ募集していません
- Severance Hospital, Yonsei University College of Medicine
-
主任研究者:
- Chi Young Shim, MD, PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Able to understand the study protocol and provide written informed consent
- Adults aged 19 years or older
- Moderate or asymptomatic severe aortic stenosis, defined as all of the following:
- Aortic valve area (AVA) less than 1.5 cm2, aortic valve peak velocity (Vmax) 3 m/s or higher, or aortic valve mean pressure gradient 25 mmHg or higher
- Left ventricular ejection fraction 50% or higher
- Asymptomatic, New York Heart Association (NYHA) functional class I
Exclusion Criteria:
- Left ventricular ejection fraction below 50%
- Indication for aortic valve intervention according to current ACC/AHA or ESC/EACTS guidelines
- Symptomatic severe aortic stenosis
- Severe stenosis or regurgitation of another valve, or concomitant severe aortic regurgitation
- Very severe aortic stenosis (aortic valve Vmax 5 m/s or higher, or mean pressure gradient 50 mmHg or higher)
- NYHA functional class II to IV
- Use of an SGLT2 inhibitor within the previous 3 months
- Known hypersensitivity to SGLT2 inhibitors
- Estimated glomerular filtration rate below 30 mL/min/1.73 m2, or on dialysis
- Type 1 diabetes mellitus
- Pregnancy or breastfeeding
- Liver disease with AST or ALT 2 or more times the upper limit of normal, or history of hepatic encephalopathy, esophageal varices, or portosystemic shunt
- Life expectancy below 2 years, or inability to comply with the study protocol
- Diabetic ketoacidosis
- Current use of medications that may affect efficacy assessment (DPP-4 inhibitors, vitamin K, calcium supplements)
- Sexually active women of childbearing potential who do not agree to use adequate contraception during the study
- Participation in another clinical trial within the previous 1 month or 5 half-lives of the investigational product
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Enavogliflozin
Enavogliflozin 0.3 mg film-coated tablet orally once daily for 24 months, in addition to guideline-directed medical therapy. |
Sodium-glucose cotransporter-2 inhibitor, 0.3 mg film-coated tablet, taken orally once daily for 24 months.
他の名前:
|
|
プラセボコンパレーター:Placebo
Matching placebo tablet (identical in appearance) orally once daily for 24 months, in addition to guideline-directed medical therapy. |
Matching placebo tablet identical in appearance to enavogliflozin, taken orally once daily for 24 months. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite of all-cause death, aortic valve replacement, or hospitalization for heart failure
時間枠:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to first occurrence of any component of the composite: all-cause death; surgical or transcatheter aortic valve replacement; or hospitalization for heart failure, defined as presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics. All events are adjudicated by an independent clinical event adjudication committee. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-cause death
時間枠:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to death from any cause after randomization. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Aortic valve replacement
時間枠:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to first surgical or transcatheter aortic valve replacement after randomization. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Hospitalization for heart failure
時間枠:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to first adjudicated hospitalization for heart failure after randomization (presentation to an acute care facility requiring an overnight stay with symptoms and signs of heart failure and treatment with intravenous diuretics, vasodilators, or inotropes, mechanical fluid removal, intra-aortic balloon pump, or initiation/doubling of oral diuretics). |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Cardiac death
時間枠:From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
Time to adjudicated cardiovascular death, including sudden cardiac death, death due to acute myocardial infarction, heart failure or cardiogenic shock, other cardiovascular causes, or death of unknown cause without an undisputed non-cardiac cause. |
From randomization until the end of study (2 years after enrollment of the last participant), up to approximately 60 months
|
|
Change from baseline in aortic valve peak velocity
時間枠:Baseline, 12 months, and 24 months
|
Change in peak aortic jet velocity (m/s) measured by transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in mean transaortic pressure gradient
時間枠:Baseline, 12 months, and 24 months
|
Change in mean transaortic pressure gradient (mmHg) measured by transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in aortic valve area
時間枠:Baseline, 12 months, and 24 months
|
Change in aortic valve area (cm2) calculated by the continuity equation on transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in dimensionless index (velocity ratio)
時間枠:Baseline, 12 months, and 24 months
|
Change in the dimensionless index (velocity ratio), defined as the ratio of left ventricular outflow tract to transaortic velocity (or velocity-time integral), measured by transthoracic echocardiography; unitless. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in left ventricular mass
時間枠:Baseline, 12 months, and 24 months
|
Change in echocardiographic left ventricular mass (g). |
Baseline, 12 months, and 24 months
|
|
Change from baseline in left ventricular global longitudinal strain
時間枠:Baseline, 12 months, and 24 months
|
Change in left ventricular global longitudinal strain (%) by speckle-tracking echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in left ventricular ejection fraction
時間枠:Baseline, 12 months, and 24 months
|
Change in left ventricular ejection fraction (%) by transthoracic echocardiography. |
Baseline, 12 months, and 24 months
|
|
Change from baseline in NT-proBNP
時間枠:Baseline, 12 months, and 24 months
|
Change in plasma N-terminal pro-B-type natriuretic peptide concentration (pg/mL). |
Baseline, 12 months, and 24 months
|
|
Annual eGFR slope
時間枠:From baseline through 24 months
|
Mean slope of change in estimated glomerular filtration rate (CKD-EPI equation), expressed as mL/min/1.73 m2 per year. |
From baseline through 24 months
|
|
Number of participants with at least one adverse event of special interest related to SGLT2 inhibition (safety)
時間枠:From first dose of study drug through 7 days after the last dose (up to approximately 25 months)
|
Number of participants experiencing one or more prespecified adverse events of special interest, reported as a single count per arm. Adverse events of special interest are: confirmed hypoglycemia (plasma glucose 70 mg/dL [3.9 mmol/L] or lower, or an event requiring assistance), urinary tract infection, genital infection, volume depletion, and acute kidney injury by KDIGO criteria. |
From first dose of study drug through 7 days after the last dose (up to approximately 25 months)
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Sung-Ji Park, MD, PhD、Samsung Medical Center
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2025-07-028
- KCT0012093 (レジストリ識別子:Clinical Research Information Service (CRIS), Republic of Korea)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be shared outside the study group because the informed consent and institutional policy do not permit external release of participant-level data. Aggregate results will be published in a peer-reviewed journal and reported to ClinicalTrials.gov.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。